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ABSTRACT
Hepatocellular carcinoma (HCC) is the most common cancer of the liver with a 
very poor prognosis. The dysregulation of microRNAs (miRs) is indeed implicated in 
HCC onset and progression. In this study, we have evaluated the expression of miR-
23b and miR-193a in a large cohort of 59 and 67 HCC patients, respectively. miR-
23b and miR-193a resulted significantly down-regulated in primary HCCs compared 
to their matched peritumoral counterparts. Furthermore, patients with higher miR-
193a expression exhibited longer OS and DFS, suggesting that miR-193a may be a 
molecular prognostic factor for HCC patients. Since the regulation of miRs by DNA 
methylation may occur in human cancers, we verified whether the down-modulation of 
miR-23b and miR-193a in HCC tissues could be related to DNA methylation. An inverse 
trend between miR-23b expression and DNA methylation was observed, indicating 
that miR-23b can be epigenetically regulated. By contrast, the down-regulation of 
miR-193a was not mediated by DNA methylation. To verify the potential role of miR-
23b and miR-193a as responsive molecular targets in vitro, we used the inhibitor 
of DNA methylation 5-aza-dC to restore miR-23b expression level in combination 
with miR-193a transfection. The combined treatment led to a significant inhibition of 
cellular proliferation and migration. Taken together, our findings provide evidence that 
miR-23b and miR-193a may be molecular diagnostic and prognostic factors for HCC; 
furthermore, miR-23b and miR-193a are responsive molecular targets for limiting 
HCC cell aggressiveness in combination with the epigenetic drug 5-aza-dC. Moreover, 
our results provide new advances in the epigenetic regulation of these miRs in HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most 
common type of primary liver cancer and it accounts 
for 80-90% of total cases. HCC represents the third 
leading cause of cancer death worldwide and due to poor 
prognosis and high incidence, it represents a malignancy 
of global importance [1, 2]. To date, surgical resection and 
orthotopic liver transplantation are considered the only 
possibly curative therapies for early stage HCC. However, 
only one third of patients are eligible for these therapies 
and long term results are not completely satisfactory [3, 4]. 
For patients with inoperable HCC, percutaneous ablation 
and chemoembolization are widely used as loco-regional 
therapeutic strategies. The sole systemic treatment 
available against advanced HCC is the oral multikinase 
inhibitor sorafenib that prolongs the overall survival (OS) 
of HCC patients from 7.9 to 10.7 months [5, 6]. However, 
some patients develop resistance to sorafenib suggesting 
that innovative molecular therapies are urgently needed.
In the last decade, several data from high throughput 
analyses have delineated the landscape of genetic 
alterations of HCC, providing important insights into the 
characterization of possible biomarkers and targets in 
order to improve prognosis of HCC patients. However, 
actually, none of this knowledge is translated into clinical 
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2016
Oncotarget2www.impactjournals.com/oncotarget
practice [7]. Consequently, a more in-depth understanding 
of HCC onset and progression is paramount to identify 
responsive molecular therapeutic targets.
Similarly, with other tumors, the pathogenesis 
of HCC is a multistep process that starts from pre-
neoplastic lesions that progress in HCC. The exposure 
to risk factors that determine or aggravate the chronic 
inflammation of the liver contributes to the accumulation 
of genetic and epigenetic alterations. This may result in 
activation of oncogenes, silencing of tumor suppressors 
genes, in microRNAs and in other non-coding RNAs 
dysregulation [8, 9]
MicroRNAs (miRNAs) are a class of endogenous, 
small non-coding RNAs (19-22 nucleotides in length) 
that regulate gene expression at post-transcriptional 
level, playing an important role in physiological 
processes, such as differentiation, apoptosis and cell 
growth. Several studies demonstrated that miRNAs are 
dysregulated in many types of cancers and contribute to 
tumorigenesis functioning both as tumor suppressor genes 
both as oncogenes (OncomiRs). Additionally, molecular 
approaches based on miRNAs may constitute a promising 
strategy for the treatment of solid tumors by relying on the 
ability of miRNAs to target different oncogenes at the same 
time [10, 11]. In recent years, the epigenetic regulation of 
miRNAs has been reported for many types of cancers. The 
enhancement of methods for measuring DNA methylation 
at specific genomic loci allowed the identification of DNA 
hyper-methylation of CpG sites within CpG islands as a 
mechanism involved in the down-regulation of miRNAs 
[12–14]. Interestingly, Kozaki and colleagues found 
that 11.6% (122/1048) of miRNAs were epigenetically 
regulated in 23 cancer types and that 19.5% of miRNA 
coding sequences had a CpG island within 5 kb upstream 
[15]. In 2008 Datta et al. individuated the first miRNA 
silenced by hypermethylation in HCC cells and tissues, 
miR-1 [16]. They also demonstrated that the ectopic 
expression of miR-1 in HCC cells reduced their aggressive 
properties and that the treatment with hypomethylating 
agent 5-Azacytidine induced the down-regulation of the 
miRNA targets FoxP1, MET and HDAC4. Subsequently 
also miR-129-2, miR-124, miR-203, miR-125b, miR-34b 
and miR-200b were recognized as novel tumor suppressor 
miRNAs epigenetically silenced in HCC [17–21].
In the context of microRNA and HCC, our previous 
results identified miR-193a as a negative regulator of 
urokinase type plasminogen activator (uPA) [22] and 
miR-23b as a negative co-regulator of uPA and MET (a 
receptor tyrosine kinase, RTK) [23], that are considered 
both unfavourable prognostic factors in HCC patients 
[24]. In this study, we first examined the expression 
of miR-23b and miR-193a in a large number of HCC 
specimens to explore their possible role as diagnostic 
and prognostic tissue molecular markers. Next, since 
bioinformatics analysis showed the presence of CpG 
islands near the coding sequences of these miRNAs we 
verified whether the DNA methylation was involved in the 
regulation of miR-23b and miR-193a expression in HCC. 
Recent studies aimed at the development of anti-cancer 
molecular approaches based on epigenetic drugs, included 
the inhibitor of DNA methylation 5-Aza-2’-deoxycytidine 
(5-aza-dC, Decitabine) that has been approved in the 
treatment of haematological malignancies and its effects 
on solid tumors were worth considering [25]. Since we 
found that DNA methylation was involved in the down-
regulation of miR-23b, but not of miR-193a, we tested the 
effects of 5-aza-dC that restored miR-23b expression, in 
combination to miR-193a transfection in HCC cells.
RESULTS
miR-23b and miR-193a are down-regulated in 
human primary HCCs
We examined the expression of mature miR-23b and 
miR-193a in human HCC specimens and their peritumoral 
(PT) counterparts by real-time qPCR. In 59 HCC patients, 
the expression of mature miR-23b was significantly lower 
in HCC specimens compared with PT tissues from the same 
patients (average RQPT = 68.63 ± 7.50, average RQHCC = 
36.60 ± 4.08, p<0.001; R [RQHCC/ RQPT]= 0.53; Figure 1A). 
Even though the overall expression of miR-23b was lower 
in HCC tissue compared to PT tissue, there were patients 
showing different trends. In particular, 38 HCC cases 
(64%) showed miR-23b down-regulation (R<0.7) while 
8 HCC cases (14%) displayed up-regulation of miR-23b 
in HCC samples with respect to PT counterparts (R>1.3). 
Conversely, 13 patients (22%) showed an equal expression 
of miR-23b when HCC and PT tissues were compared 
(0.7<R<1.3; Supplementary Figure S1A). Among the 
67 HCC patients tested, miR-193a resulted significantly 
down-regulated in HCC compared to PT tissues (average 
RQPT = 3.13 ± 0.47; average RQHCC = 1.80 ± 0.33; p<0.01; 
R [RQHCC/ RQPT] = 0.58; Figure 1B). As for miR-23b, 
individual patients showed different trends. We found that 
miR-193a was down-regulated in 43 HCC cases (64%) 
while it was up-regulated in 14 HCC cases (22%) compared 
with corresponding PT tissues. Ten cases (10/67, 15%) had 
no change in miRNA expression level between HCC and 
PT tissues (Supplementary Figure S1B). To evaluate the 
correlation between miR-23b and miR-193a expression 
and clinical pathological characteristics, the patients were 
divided into 2 groups with high (R>0.8) and low (R<0.8) 
miR expression. However, non-significant correlations 
were observed between miRs expression and clinical and 
pathological characteristics (Supplementary Table S1). 
ROC curve and Kaplan-Meier analysis were performed to 
prove the diagnostic and prognostic significance of miR-
23b and miR-193a in HCC. Areas under ROC curve (AUC) 
of 0.73 (95% CI = 0.64-0.82; p<0.001) and 0.71 (95% CI = 
0.62-0.80; p<0.001) were obtained for miR-23b and miR-
193a, respectively (Figure 1C). These results suggested that 
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Figure 1: Expression of mature miR-23b and miR-193a in HCC and peritumoral specimens. The expression of miR-23b 
and miR-193a was detected separately by stem-loop qPCR in 59 and 67 HCC patients, respectively, from both HCC tissues and PT 
samples. The expression of mature miR-23b A. and miR-193a B. was generally lower in HCCs compared to corresponding PT counterparts. 
Statistical significance was determined by paired t-test analysis ***p<0.001 and **p<0.01. C. ROC analysis for the ability of miR-23b 
and miR-193a expression to discriminate between HCC and PT tissues. Kaplan-Meier analysis was performed for overall survival (OS) 
and disease free survival (DFS) based on the expression miR-23b D. and miR-193a E. where miR-H indicates high miR expression groups 
while miR-L indicates the low miR expression group.
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the expression of miR-23b and miR-193a may discriminate 
HCC from PT samples with fair accuracy in the cohort 
examined. To conduct the Kaplan-Meier analyses on the 
30 cases available, we divided HCC samples into group 
with high miR expression (R>0.8) and low miR expression 
(R<0.8). No significant difference was reported in the OS 
and the disease-free survival (DFS) were found between 
cases with higher miR-23b expression compared with lower 
expression (Figure 1D). Conversely, the group with higher 
miR-193a expression had a significantly increased OS 
and DFS than the group with down-regulated miR-193a. 
In fact, the higher miR-193a expression group median OS 
was of 89 months compared with 39.5 months of the group 
with lower miR-193a expression (Log-Rank test p<0.05). 
The median DFS for the group of patients with higher miR-
193a expression was of 62 months while the same value 
for the group with lower miR-193a expression was of 18 
months (Log-Rank test p<0.05; Figure 1E).
DNA methylation is involved in the regulation of 
miR-23b expression in primary HCC
In order to understand whether the modulation of 
miR-23b and miR-193a in HCC tissues was mediated 
by DNA methylation, we compared the level of DNA 
methylation and miRs expression in 30 HCC cases more 
recently collected. DNA methylation level was detected 
by MS-PCR (Supplementary Figure S2) and mature miRs 
expression was examined by qPCR. As shown in Figure 
2A, miR-23b coding sequence was preceded by two CpG 
Figure 2: DNA methylation levels of miR-23b and miR-193a and relative expression in primary HCCs (N=30). A. 
Schematic illustration of chr 9 and chr 17 where miR-23band miR-193a coding sequences are located, respectively. CpG islands in light 
grey and relative GC percentage were shown in a region spanning 1,000 bp upstream of each miR. Each small vertical bar indicates a single 
CG dinucleotide and the regions examined by MS-PCR are represented below.DNA methylation and miRs expression levels are reported 
for miR-23b B-C. respectively and miR-193a D-E. respectively. Histograms indicate the average level of methylation detected with MS-
PCR or the mean RQ obtained in qPCR while bars show SEM. (B) The methylation level of miR-23b was significantly higher in HCC than 
in PT tissues while the expression level was lower (C), indicating an inverse trend between DNA methylation and miRNA expression.For 
miR-193a, both methylation (D) and expression (E) levels were decreased in HCC specimens respect to PT counterparts. F. In the group of 
HCCs displaying miR-23b down-regulation, the methylation level was significantly higher than in PTs; no difference in DNA methylation 
was observed in the group of HCCs with equal or up-modulation of the miRNA. G. For miR-193a, DNA methylation level was decreased 
in HCC samples in both down-modulated and up-modulated groups. *p<0.05, **p<0.01, ***p<0.001 in paired t-test analysis.
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islands (141bp and 101bp in length, respectively) in a 
1.0kb upstream region while miR-193a coding sequence is 
embedded in a CpG island (1,477bp in length). The results 
obtained in MS-PCR and qPCR showed an inverse trend 
between DNA methylation level and miR-23b expression. 
In fact, average methylation level was significantly 
higher (p<0.01; Figure 2B) and miR-23b expression was 
significantly lower (p<0.01; Figure 2C) in HCC tissues 
compared with PT tissues. On the contrary, the average 
methylation level of miR-193a at CpG sites resulted 
significantly reduced in HCC respect PT counterparts 
(p<0.001; Figure 2D) with the miRNA generally down-
regulated in this group of HCC cases (Figure 2E). To 
analyze further, we divided the HCC samples into two 
groups according to the expression of each miRNA where 
R<0.7 indicated miRNA down-modulation and R>0.7 
indicated that the miRNA was equal- or up-modulated in 
HCC compared to PT tissues. Interestingly, the average 
methylation level of miR-23b in the first group was 
significantly higher in HCC than PT tissues (p<0.05) while 
no difference was observed in the second group (Figure 
2F). On the contrary, methylation level of miR-193a was 
significantly lower in HCCs, uncoupled with miRNA 
expression level (Figure 2G). These findings suggested 
that the methylation of CpG sites examined was involved 
in the down-regulation of mature miR-23b in primary 
HCC, but not in miR-193a down-regulation. However, 
the lack of an association between DNA methylation and 
miR-23b expression in the HCC group with up-modulated 
miRNA hinted at the presence of additional mechanisms 
taking part in the regulation of miR-23b in human HCCs 
and probably also in miR-193a regulation.
Treatment with 5-aza-dC restored miR-23b 
expression in cultured HCC cells
Since the over-expression of miR-23b decreased 
proliferation and migration abilities of HCC cells [23], 
we evaluated whether treatment with the inhibitor of 
DNA methylation 5-aza-dC could induce up-regulation 
of miR-23b in HCC-derived cells. Firstly, the expression 
levels of miR-23b and miR-193a were examined in 
different HCC cell lines. Stem-loop qPCR revealed that 
miR-23b was detected at low level in undifferentiated 
HCC cells (HA22T/VGH and SKHep1C3) and it was 
moderately expressed in differentiated HepG2 cells 
(Figure 3A). On the contrary, miR-193a expression level 
was moderate in HA22T/VGH and SKHep1C3 and very 
Figure 3: Expression and methylation levels of miR-193a and miR-23b in HCC cell lines. A-B. miR-23b and miR-193a 
expression levels, respectively, were detected by stem-loop qPCR in human HCC cells. Histograms represent the mean RQ while bars 
represent RQ maximum and minimum values. C. MS-PCR analysis showed that miR-23b CpG sites resulted partially methylated and the 
treatment with 5-aza-dC led to their demethylation. D. miR-193a CpG sites were completely unmethylated in undifferentiated HCC cells 
and partially methylated in HepG2. The treatment with 5-aza-dC induced the demethylation of analysed site in HepG2. The percentage of 
DNA methylation (IOD M/IOD M + IOD U × 100) is indicated for each sample. E-F. 5-aza-dC treatment significantly increased mature 
miR-23b expression in SKHep1C3 and mature miR-193a expression in HepG2, respectively; mean of three experiments ± SEM are 
reported; *p<0,05 using unpaired t-test analysis.
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low in HepG2 cells (Figure 3B). Regarding the level of 
DNA methylation, miR-23b CpG sites resulted partially 
methylated in HCC cells as detected by MS-PCR. In 
particular, the band specific for methylated sequence 
was predominant with a percentage of methylation equal 
or greater than 60% in all HCC cell lines (Figure 3C). 
Furthermore, miR-193a CpG sites resulted completely 
unmethylated in HA22T/VGH and SKHep1C3 cells and 
68% methylated in HepG2 cells (Figure 3D). Treatment 
with 5-aza-dC reduced the methylation level of miR-23b 
CpG sites in all cell lines but particularly in HA22T/
VGH and HepG2 cells. However, the reduction of 
methylation in HA22T/VGH and HepG2 cells did not 
lead to a significant difference in miR-23b expression 
(Figure 3E). Interestingly, SKHep1C3 cells showed only 
a modest reduction in methylation but were evidently 
more sensitive to demethylation since mature miR-
23b expression significantly increased (p<0.05) in cells 
after treatment with the inhibitor of DNA methylation 
compared with untreated cells (Figure 3E). Similarly, 
5-aza-dC treatment in HepG2 cells led to the decrease in 
methylation level of miR-193a CpG sites (Figure 3D) and 
39% increase in mature miR-193a expression (p<0.05; 
Figure 3F). All together, these results showed that the 
methylation of DNA contributed to the regulation of miR-
23b in SKHep1C3 cells and miR-193a in HepG2 cells.
Effects of miR-193a ectopic expression and 
5-aza-dC treatment on expression of MET and 
uPA
Since 5-aza-dC treatment induced the expression 
of miR-23b in SKHep1C3 cells, we hypothesized that 
by combining the inhibitor of DNA methylation with 
miR-193a transfection it could be possible to re-establish 
the homeostatic level activities of miR-23b and miR-
193a. In our previous published studies [22, 23] we have 
demonstrated that miR-23b and miR-193a negatively 
regulated the expression of uPA and MET in HCC cells. 
For this reason we examined whether the combined use 
of 5-aza-dC and miR-193a transfection might alter the 
expression of MET and uPA. For this purpose, MET and 
uPA protein expression was evaluated by western blot 
in SKHep1C3 cells treated with 10 μM 5-aza-dC alone 
or in combination with 100 nM miR-193a. The receptor 
tyrosine kinase MET is synthesized as a precursor protein 
of 170 kDa that is cleaved to yield a 50-kDa α-chain and a 
145-kDa β-chain linked together by disulfide bonds. After 
5 days, there was a 2.2 fold decrease in the MET β-chain 
expression level (equivalent to 55%) in cells treated with 
10 μM 5-aza-dC as compared with the control exposed to 
DMSO only (p<0.05; Figure 4A). The reduced expression 
of MET protein was also observed in cells treated with 
Figure 4: Effects of combined treatment with 5-aza-dC and miR-193a on MET and uPA protein expression levels. 
SKHep1C3 cells were treated with DMSO (vehicle) and 10 μM 5-aza-dC for 5 days (lanes 1 and 2) or treated with 10 μM 5-aza-dC in 
combination to 100 nM miR-193a transfection (lanes 5 and 8) and relatives controls (lanes 3, 4, 6 and 7) at 24h and 48h from transfection. 
Western blot was performed to detect MET and GAPDH expression A. on cell extracts and uPA expression B. and corresponding enzymatic 
activity C. on conditioned medium. The histograms represent the mean IOD (Integrated Optical Density) values in percentage while bars 
are SEM. *p<0.05 using unpaired t-test analysis.
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10 μM 5-aza-dC and transfected with 100 nM miR-
193a where 32% and 20% decrease at 24h and 48h after 
transfection, respectively, was observed when compared 
to cells treated with DMSO and lipofectamine alone. 
In contrast, uPA protein level was up-regulated by 23% 
after 5-aza-dC treatment and by 50% after co-treatment 
with 5-aza-dC and miR-193a at 48h from transfection, as 
compared with corresponding controls (Figure 4B). The 
corresponding enzymatic activity evaluated in zymography 
confirmed the trend of uPA protein expression (Figure 
4C). To support the above mentioned results, we treated 
2 more HCC cell lines (HepG2 and HA22T/VGH) with 
the DNA methylation inhibitor 5-aza-dC and miR-193a to 
verify whether uPA and MET expression may be affected. 
In HepG2 and HA22T/VGH cells the MET expression 
level decreased in 5-aza-dC treated cells and in the co-
treated cells, in line with the results found in SKHep1C3 
(Supplementary Figure S3A and Supplementary Figure 
S3C). uPA protein expression did not change in HepG2 
following combined treatments (Supplementary Figure 
S3B) and its enzymatic activity was undetectable (data 
not shown); in HA22T/VGH cells uPA protein and its 
enzymatic activity resulted inhibited following 5-aza-dC 
and miR-193a combined treatment (Supplementary Figure 
S3D and Supplementary Figure S3E).
5-aza-dC treatment and miR-193a ectopic 
expression decreased the proliferation and 
migration of HCC cells
To determine the biological effects of 5-aza-
dC treatment in combination with miR-193a ectopic 
expression, we pre-treated SKHep1C3 cells with 10 μM 
5-aza-dC followed by transfection with synthetic pre-
miR-193a at 50 and 100 nM doses and monitoring of cell 
growth, as described in the Materials and Methods section. 
The MTT assay data showed no significant difference 
of cell viability after miR-193a transfection, while the 
treatment with 5-aza-dC alone decreased cell growth by 
up to 18% at 48h after the last treatment as compared with 
untreated cells (Figure 5A). The combination of miR-193a 
transfection and 5-aza-dC treatment further significantly 
reduced cell proliferation. Particularly when 100 nM of 
miR-193a was used, the cell growth decreased up 32% 
(p<0.001) at 48h after transfection as compared with 
control cells (DMSO treated and miR-NC transfected).
The inhibition of cell growth was not observed at 72h 
suggesting that 5-aza-dC treatment and miR transfection 
had a transient effect on proliferation. In these conditions, 
the expression levels of mature miR-23b was increased 
up to 72% following 5-aza-dC treatment and miR-193a 
transfection (Supplementary Figure S4A); miR-193a 
was upregulated up to 168 folds (Supplementary Figure 
S4B) after ectopic miR-193a transfection as verified by 
qPCR. Further, we evaluated the effects of 5-aza-dC and 
miR-193a transfection on SKHep1C3 cell migration. The 
treatment with 5-aza-dC alone decreased cell migration 
by 23% as compared with untreated cells (Figure 5B). 
The combination of miR-193a transfection and 5-aza-dC 
treatment further significantly reduced cell migration up to 
56% (p<0.001) at 100nM miR dose concentration.
Subsequently, we verified whether a combined 
approach based on the co-administration of a low dose 
sorafenib (5 μM) in combination with 5-aza-dC or 5-aza-
dC plus miR-193a could show a major inhibitor effect 
on HCC cell proliferation. As shown in Figure 5C, at T1 
(48h) sorafenib alone displayed the highest inhibition 
of cell proliferation (37% decrease against DMSO 
alone, p<0.001) compared to miR-193a transfection and 
5-aza-dC treatment. The combinations of 5-aza-dC plus 
sorafenib and sorafenib plus miR-193a significantly 
reduced cell proliferation ability compared to relative 
controls (39% and 46% decrease against DMSO and 
miR-NC + DMSO respectively; p<0.001). The same 
effect was observed after the co-administration of the 3 
treatments (42% reduction, p<0.001) as compared with 
untreated cells (miR-NC + DMSO). After 72 hours (T2) 
from miR-193a transfection, only sorafenib maintained its 
inhibitory effect on cell proliferation, even if to a lower 
level (20% compared to DMSO). These findings suggested 
that the combination of 5-aza-dC treatment and miR-193a 
ectopic expression induced a considerable inhibition of 
proliferation and migration in HCC cells; furthermore the 
addition of sorafenib to 5-aza-dC, in presence or not of 
miR-193a, did not increase the inhibitory effects on cell 
viability carried out by the treatment with sorafenib alone.
Effects of miR-23b and miR-193a ectopic 
expression on the proliferation and migration of 
HCC cells
Since 5-aza-dC determines global changes in gene 
expression, we tested whether co-transfection of low doses 
miR-23b and miR-193a in SKHep1C3 cells may impair 
the cell proliferation and migration in order to compare 
the effects provoked by 5-aza-dC and miR-193a treatment. 
The combined transfection did not induce additive cell 
proliferation inhibition (Figure 6A). The major effect was 
observed 24 h after 50 nM miR-23b transfection (20%, 
p<0.05). The migration ability of SKHep1C3 was inhibited 
after miR-23b and miR-193a single transfection and an 
additive trend was found following the co-transfection 
with miRs (Figure 6B).
DISCUSSION
In previously published studies, we have 
demonstrated that miR-23b directly targeted both MET 
and uPA in HCC cells and that the ectopic expression of 
miR-23b reduced proliferation and migration abilities of 
HCC cells [23]. More recently, we found that miR-193a 
negatively regulated uPA and the transfection of HCC 
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Figure 5: Ectopic expression of miR-193a in combination to 5-aza-dC treatment decreased proliferation and migration 
abilities of SKHep1C3 cells. A. The MTT assay showed that the combined treatments with 5-aza-dC and miR-193a ectopic expression 
inhibited the growth of SKHep1C3 cells at T1 (48h) compared to controls and miRNA transfection alone. Histograms represent mean 
values of two experiments while bars represent SEM. *** p<0.001 in one-way ANOVA followed by Tukey test B. Scratch wound healing 
assay was performed to asses migration ability. Representative phase contrast images with magnification 10X at T0, T1 (20 hours) and T2 
(30 hours) after wound are reported. Histograms represent the mean value of migration rate (scratch width T0 - scratch width T2/ scratch 
width T0); error bars are the SEM. ***p<0.001, *p<0.05 using one-way ANOVA followed by Tukey test. C. SKHep1C3 cells were treated 
with the indicated concentrations of 5-aza-dC, miR-193a and sorafenib, alone or in combination and the effects on cell proliferation were 
assessed by MTT assay. Results are representative of one of three experiments. The histograms represent averaged values of five replicates 
for each condition plotted as fold increased respect to SKHep1C3 cells; bars represent SEM. One-way ANOVA followed by Tukey test was 
used and ***p<0.001.
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cells with miR-193a decreased cell growth, increased 
apoptosis and sensitized the HCC cells to sorafenib [22]. 
In the present study carried out using a large cohort of 
patients with HCC, we found that miR-23b and miR-193a 
were significantly down-regulated in HCC specimens 
compared with peritumoral (PT) counterparts and the 
expression of both miRs could be used as a marker of 
diagnosis at molecular level. Moreover, the low expression 
of miR-193a resulted significantly related to reduced 
overall survival (OS) and disease free survival (DFS) of 
patients. The latter finding confirmed and complemented 
the results reported by Liu et al. that examined miR-193a 
expression in 95 formalin-fixed paraffin-embedded (FFPE) 
HCC tissues and corresponding PT [26].
In the recent years, epigenetic alterations have been 
highlighted as key factors during cancer development 
and progression; among which, aberrant methylation of 
CpG dinucleotides has been the best studied epigenetic 
modification in cancer, including HCC. Changes in 
DNA methylation level emerge at the early stage of 
hepatocarcinogenesis, affecting both coding and non-
coding genes, such as genes encoding miRNAs [27, 28]. 
Figure 6: Effects of miR-23b and miR-193a ectopic expression on the proliferation and migration of SKHep1C3 
cells. MTT assay A. and scratch wound healing assay B. were performed in SKHep1C3 cells transfected with 50 nM of miR-NC, 50 nM 
of miR-193a, miR-23b, or a half dose of miR-193a + miR-23b. (A) Ectopic expression of miR-23b significantly decreased proliferation 
after 24 hours and 72 hours from transfection compared to controls. No additive effects were detected using miR-193a and miR-23b. The 
histograms represent averaged values of five replicates for each condition; bars represent SEM. One-way ANOVA followed by Tukey test 
was used and **p<0.01; *p<0.05. Results are representative of one of two experiments. (B) Representative phase contrast images with 
magnification 10X at T0, T1 (20 hours) and T2 (30 hours) after wound are reported. Histograms represent the mean value of migration rate 
(scratch width T0 - scratch width T2/ scratch width T0) for each sample; error bars are the SEM.
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A number of miRNAs are found epigenetically silenced 
by DNA hypermethylation and their dysregulation usually 
resulted in the alteration of important pathways involved 
in carcinogenesis. Here, for the first time, we have found 
that DNA hyper-methylation was involved in the miR-23b 
down-modulation in HCC because we reported an inverse 
trend between DNA methylation and miR-23b expression 
in primary HCC. In line with this finding, miR-23b was 
found to be silenced by hypermethylation in prostate 
cancer tissues and cell lines [29], in glioma stem cells [30] 
and cervical cancer cell lines [31]. On the contrary, in the 
same HCC cases analysed the miR-193a down-modulation 
was not associated to a hyper-methylation of the miR-
193a-related CpG island. Previous studies concerning 
miR-193a showed that it is regulated by DNA methylation 
in oral cancer and in non-small cell lung cancer [32, 
33] and acute myeloid leukemia [34]. Therefore, we 
hypothesized that other mechanisms could take part in 
miR-193a regulation in HCC. Among these, Max and 
RXRα were reported as two transcription factors that bind 
directly miR-193a regulatory region and inhibit miR-193a 
expression in ER-Src transformed cells [35]. Furthermore, 
like protein-coding genes, miRNAs expression can be 
closely associated to histone modifications. Data obtained 
using miRNA microarray analysis showed that HDAC 
inhibitors modulated the expression of several miRNAs 
also in HCC cell lines [36, 37].
The next aim of the present work was the 
identification of an HCC in vitro model to modulate 
miR-23b and miR-193a expression. The analyses of 
DNA methylation level reported that miR-23b was 
methylated in all 3 HCC cell lines examined at low miR-
23b expression level and miR-193a was methylated 
in differentiated HepG2 cells. On the contrary, in 
undifferentiated HCC cell lines, miR-193a resulted 
completely unmethylated. Previously, Ma et al. indicated 
that the 5-Fluorouracil-sensitivity of HCC cells, including 
HepG2, was related to the down-regulation of miR-193a 
mediated by DNA hypermethylation. They also showed 
the total demethylation of miR-193a in different HCC 
cell lines [38], in agreement with our results. In addition, 
in malignant pleural mesothelioma cells that displayed 
downregulation of miR-193a, this miR was detected 
unmethylated [39]. About the demethylating effects, we 
showed that miR-23b levels increased after treatment with 
the DNA methylation inhibitor 5-aza-dC in SKHep1C3 
and in HepG2 cells. This increased sensitivity to inhibitor 
of DNA methylation coupled with the observation that 
DNA methylation levels of miR-23b and miR-193a were 
in line with those observed in HCC specimens supported 
our decision to use the SKHep1C3 cells to modulate miR-
23b and miR-193a expression.
In recent years, the advances in the knowledge of 
epigenetics, suggested the use of epigenetic drugs for the 
treatment of solid tumors to obtain the demethylation 
of tumor suppressor genes and miRs at epigenomic 
level. Inhibitor of DNA methylations such as 5-Aza-2’-
deoxycytidine and 5-Azacytidine have been approved 
for the treatment of myelodysplastic syndrome and 
their effects on apoptosis and senescence have been 
established in HCC cells [40, 41]. In order to define a 
design of a responsive experimental treatment approach 
based on the modulation of miR-23b and miR-193a, we 
attempted to restore miR-23b and miR-193a respectively 
by 5-aza-dC treatment and ectopic miR-193a expression 
in SKHep1C3 cells and we assessed the expression 
levels of the miR-23b and miR-193a targets, uPA and 
MET. Data obtained in western blot analysis conducted 
in SKHep1C3 cells and in 2 more cell lines (HepG2 and 
HA22T/VGH) were consistent with the hypothesis that 
global DNA demethylation downregulates MET through 
the activation of intracellular mechanisms, including 
increase of endogenous miR-23b. For example, it has 
been shown that DNA demethylation activates a fusion 
transcript LINE-1-MET that reduces the expression of 
MET in colon carcinoma cells [42]. Conversely, 5-aza-
dC treatment with or without miR-193a transfection 
increased uPA protein levels in SKHep1C3 cells thus 
indicating that the ectopic expression of miR193a and the 
miR-23b upregulation induced by 5-aza-dC treatment had 
minor effects on uPA expression. However, in HA22T/
VGH cells uPA protein and its enzymatic activity resulted 
unchanged in 5-aza-dC treated cells and inhibited in co-
treated cells suggesting a major role of miR-193a toward 
its target uPA in these cells. In HepG2 cells at very low 
levels of uPA protein expression, the effects of 5-aza-
dC with or without miR-193a were almost undetectable. 
Further investigations will examine whether this uPA 
overexpression may be due to DNA demethylation of 
its promoter or to other mechanisms in these 3 different 
HCC cells. Concerning the aggressive properties, our 
data indicated that the miR-193a ectopic expression 
and the 5-aza-dC treatment applied independently had 
a very low effect on inhibition of cell growth. Instead, 
in combination 5-aza-dC and miR-193a significantly 
decreased cell proliferation and migration abilities. 
These findings suggested that the ectopic expression of 
miR-193a may sensitize HCC cells to 5-aza-dC probably 
by acting on pathways not directly linked since they 
individually had a marginal effect. The combination of 
5-aza-dC plus the oral multikinase inhibitor sorafenib, 
with or without miR-193a, did not show additional 
effects respect the use of low-dose sorafenib alone which 
had a more stable growth inhibitory effect in HCC cells. 
However, a recent phase I/II study confirmed the efficacy 
and safety of lower-dose 5-aza-dC based treatment that 
improved PFS (progression-free survival) and OS of 4 
and 11 months respectively in patients with advanced 
HCC [43]. Therefore, it could be deduced that 5-aza-dC 
can be an option for the treatment of HCC, especially 
in patients not responsive to sorafenib or in patients 
developing resistance.
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In summary, our results have shown that the miR-
23b and miR193a down-modulation could significantly 
contribute to the molecular characterization of HCC 
diagnosis and that miR-193a may be a molecular 
prognostic factor for HCC patients; that DNA methylation 
mediates the miR-23b, and not miR-193a expression in 
human primary HCC. For biological activities of these 
miRs, only ectopic expression of miR-23b led to a 
significant proliferation inhibition of HCC cells and both 
miRs ectopic expression generated a strong inhibiting 
effect on migration abilities of HCC cells. Further, our 
finding of the increase of miR-23b expression in cultured 
HCC cells following 5-aza-dC treatment raises a novel 
issue to be elucidated on markers of treatment efficacy.
MATERIALS AND METHODS
Clinical samples of HCC
All human HCC samples and their corresponding 
PT non-tumour samples (resected 1–2 cm from the 
malignant tumour) were obtained from HCC patients 
undergoing surgical resection. Each biopsy specimen 
was obtained with the informed consent of patient 
under standard conditions of sampling and processing, 
as previously described and the procedures followed 
were in accordance with standards of ethics committee 
(NP1230) [23]. None of the patients had previously 
received therapeutic treatment. A total of 59 and 67 HCC 
patients were considered for miR-23b and miR-193a 
expression analyses, respectively, including the subsets 
of HCC patients evaluated beforehand: 17 for miR-23b 
[23] and 39 cases for miR-193a [22]. Each specimen was 
determined to be HCC or PT by pathological examination. 
The characteristics of the patients are described in 
Supplementary Table S2 and Supplementary Table S3.
Cell cultures and treatments
The following human HCC cell lines were used in 
this study: HA22T/VGH (undifferentiated HCC-derived 
cells provided by Prof. N. D’Alessandro, University of 
Palermo, Italy), HepG2 (differentiated HCC-derived 
cells; ATTC HB-8065) and SKHep1Clone3 (SKHep1C3), 
selected from human HCC-derived cells (SKHep1: ATCC 
HTB-52). HA22T/VGH cells were maintained in RPMI-
1640 (Life Technologies) while HepG2 and SKHep1C3 
were maintained in Earle’s MEM. Both media were 
supplemented with 10% foetal bovine serum and cells 
were grown at 37°C with 5% CO2. 5-Aza-2’-deoxycytidine 
(5-aza-dC; Sigma-Aldrich) was dissolved in DMSO 
(Sigma, St. Louis, MO) at the concentration of 50 mg/ml. 
To study DNA methylation levels, HCC cell lines were 
treated with 10 μM 5-aza-dC for 10 days (HA22T/VGH 
and HepG2) or for 5 days (SKHep1C3). Culture medium 
containing freshly added 5-aza-dC was replaced every 48 
h. DMSO was added to cultures at 0.01% (v/v) as a solvent 
control. Sorafenib [N-(3-trifluoromethyl-4-chlorophenyl)-
N-(4-(2-methylcarbamoylpyridin-4-yl) oxyphenyl) urea] 
was synthesized at Bayer Corporation (West Haven, CT). 
This compound was dissolved in DMSO and diluted with 
MEM to have a final concentration of 5 μM.
Real-time quantification of mature miRNAs by 
stem–loop RT-PCR
The total RNAs were isolated from tissue samples 
and cells using TRIzol reagent (Invitrogen), according to 
the manufacturer’s instructions. Mature miR-193a and 
miR-23b were quantitated by a two-step Taq-Man real-
time PCR analysis, using primers and probes obtained 
from Applied Biosystems (Foster, CA, USA). cDNA was 
synthesized from total RNA (50 ng) in 15 μl reactions, 
using reverse transcriptase and the stem–loop primer for 
miR-193a (Applied Biosystems; PN 4427975), miR-23b 
(Applied Biosystems; PN 4373073) or RNU66 (internal 
control; Applied Biosystems; PN 4373382) contained in 
the TaqMan MicroRNA Reverse Transcription kit (Applied 
Biosystems, Foster, CA, USA). The reverse transcription 
reaction was performed by incubating the samples at 
16°C for 30 min, followed by incubation at 42°C for 30 
min and 85°C for 5 min. The q-RT PCR reaction (20 μl) 
contained 1.3 μl of reverse transcription product, 10 μl of 
Taq-Man 2× Universal PCR Master Mix and 1 μl of the 
appropriate TaqMan MicroRNA Assay (20×) specific for 
the miRNA targeted by the assay. The PCR mixtures were 
incubated at 95°C for 10 min, followed by 40 cycles at 
95°C for 15 s and 60°C for 60 s. PCRs were performed in 
triplicate using the 7500 real time PCR system (Applied 
Biosystems). The expression of miR-193a and miR-23b 
was based on the ∆∆CT method, using RNU66 as an 
internal control. For each case the ratio (R= RQHCC/RQPT) 
between the relative levels in HCC and those in PT was 
assessed. The level of miRNAs expression was considered 
to be decreased for R values below 0.7 and increased for R 
values above1.3. When values were between 0.7 and 1.3, 
the miRNA expression was considered unchanged.
DNA isolation and bisulfite modification
Genomic DNA was extracted from HCC cell 
lines (HA22T/VGH, HepG2 and SKHep1C3 treated 
or not with 5-aza-dC) and tissue samples (HCC and the 
corresponding PT), using the Wizard Genomic DNA 
Purification Kit (Promega) and the Blood Core Kit B 
(Qiagen), respectively, according to the manufacturer’s 
instructions. To verify the integrity of genomic DNA, 
100 ng of each sample was loaded on ethidium bromide-
stained 0.8% agarose (w/v) gel and visualized as a high 
molecular weight single band. Bisulfite treatments of 
DNA were performed with EZ DNA Methylation Kit 
(Zymo Research), which allow purification and recovery 
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of converted DNA in Zymo-Spin IC Columns. Bisulfite 
conversion was carried out on 1 μg of DNA for each 
sample, in the dark at 50°C for 12-16 hours.
Methylation analysis of CpG sites associated 
with miR-193a and miR-23b by methylation-
specific PCR (MSP)
Methprimer (http://www.urogene.org/methprimer) 
was used to verify the presence of CpG islands in the 
1.0 kb upstream sequences of miR-193a and miR-23b. 
To investigate the methylation of miRs CpG sites, 
methylation-specific PCR (MS-PCR) was performed. 
Bisulfite-converted DNA was amplified using primer 
sets specific for the methylated sequence (primers 
M) and the unmethylated sequence (primers U). The 
methylation-specific and unmethylation-specific 
primers were designed by MethPrimer (http://www.
urogene.org/methprimer/; Supplementary Table S4). 
Hot start-PCR was performed in the following way: a 
cycle of denaturation at 95°C for 5 min, followed by 
40 (miR-193a) or 37 (miR-23b) cycles at 94°C for 30 
s, 57°C for 30 s, 72°C for 30 s, and a final extension 
at 72°C for 3 min. MS-PCR products were visualized 
on ethidium bromide-stained 2% agarose (w/v) gel. The 
bands corresponding to methylated and unmethylated 
DNA were analyzed using a digital system (Gel-Pro 
Analyzer) and the integrated optical density (IOD) values 
were expressed in pixel. The percentage of methylation 
level in each sample was obtained using the following 
formula: IOD band Methylated/(IOD band M + IOD 
band Unmethylated) × 100.
Transient transfection of miR-23b and miR-193a 
and 5-aza-dC/sorafenib treatments of HCC cells
Molecules of dsRNAs that mimic endogenous-
miR-23b (5’-AUCACAUUGCCAGGGAUUACC-3’), 
miR-193a (5’-AACUGGCCUACAAAGUCCCAGU-3’) 
and pre-miRNA precursor negative control #1 (Life 
Technologies) were transfected into SKHep1C3 
cells using Lipofectamine transfection reagent (Life 
Technologies), according to the manufacturer’s 
instruction. To evaluate the effect on cell proliferation 
of miR-193a/miR-23b transfection in combination 
with 5-aza-dC treatment (or 5-aza-dC and sorafenib 
treatment), SKHep1C3 cells were pre-treated with 10 
μM 5-aza-dC for 48 h and then trypsinized and seeded 
in 96-well plates (5 replicates for each experimental 
condition) at a density of 4 x 103 cells/well in complete 
culture medium supplemented with 10 μM 5-aza-
dC. Twenty-four hours after seeding, the cells were 
transfected with 50 and 100 nM pre-miR-193a into 
serum-free MEM containing 10 μM 5-aza-dC. After 5 h, 
the transfection medium was replaced with the complete 
medium supplemented with 5-aza-dC (or 10 μM 5-aza-
dC combined with 5 μM sorafenib or 5 μM sorafenib 
alone, according to experimental conditions).
Cell proliferation assay
The cellular proliferation was analysed using the 
CellTiter 96 Aqueous One Solution reagent (Promega, 
San Diego, CA, USA) after the pre-miR-193a/23b, pre-
miR precursor negative control #1 (Life Technologies) 
transfections and 5-aza-dC/sorafenib treatments. The 
cells were seeded in 96-well plates (5 replicates for each 
experimental condition) at a density of 4 × 103 cells/
well in a complete cultured medium and 15 μl/well of 
sterile CellTiter reagent was added at the established time 
after transfection and/or 5-aza-dC/sorafenib treatments. 
The plates were measured 2 h after CellTiter addition 
using a microplate reader (EnSight, Perkin Elmer). The 
absorbance values at 490 nm were directly proportional to 
the number of living cells in the culture.
In vitro scratch assay
120,000 SKHep1C3 cells were seeded in 24-well 
plate in complete medium, they were grown to 80% 
confluency and then transfected with 50 nM and 100 
nM pre-miR-23b/pre-miR-193a or/and treated with 10 
μM 5-aza-dC. After 24 h the transfection medium was 
replaced with fresh medium. When the cells reached 
the 100% confluence a scratch was made through the 
cell layer using a sterile micropipette tip. After washes 
with PBS, serum-free medium was added. The images 
of the wounded area were captured immediately after 
the scratch (T0) and 20 and 30 h later (T1 and T2) to 
monitor the cell migration into the wounded area. The 
migration abilities were quantified by measuring the 
area of the scratched regions using the ImageJ software. 
The experiment was performed twice.
Western blot and zymography
The cellular extracts and media were collected 
from 24 h and 48 h cultures of SKHep1C3, HA22T/
VGH and HepG2 cells under the following experimental 
conditions: cells treated with 10 μM 5-aza-dC for 5 
days, cells treated with 10 μM 5-aza-dC and transfected 
with 100 nM miR-193a and control cells (DMSO and 
DMSO + Lipofectamine, respectively). To evaluate 
the levels of MET and GAPDH expression, cells were 
lysed in 0.05% SDS and constant amounts of protein 
were loaded on 4-12% Novex NuPAGE Bis/Tris gels 
(Invitrogen) under reducing conditions. To detect uPA 
expression, proteins contained in the conditioned media 
were separated using 8% SDS polyacrylamide gels 
under non-reducing conditions and electro-transferred 
on nitrocellulose membranes (NM). The following 
primary antibodies were used: rabbit anti-human MET 
(1:1000 in 0.3% BSA; Santa Cruz Biotecnology), mouse 
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monoclonal antibodies anti-GAPDH (1:500 in 1% BSA; 
Merck Millipore) and rabbit anti-human uPA (1:1000 in 
1% BSA; Technoclone). Primary antibodies were stained 
using alkaline phosphatase-conjugated anti-rabbit or anti-
mouse IgG (1:7500 in 0.3% BSA; Promega). The results 
of the immunoreaction were detected with Western Blue 
Stabilized Substrate for Alkaline Phosphatase (Promega). 
Protein bands were visualized and analyzed using the Gel-
Pro Analyzer software and the integrated optical density 
(IOD) values were expressed in pixels. uPA activity was 
evaluated in zymography in which NMs were overlaid 
onto casein agar containing 2 μg/ml human plasminogen 
(Technoclone).
Statistical analysis
Statistical analyses were performed using GraphPad 
Prism 6.01. Student’s t-test was used to determine the 
differences of miRNAs expression and DNA methylation 
between HCC and PT samples and between 5-aza-dC 
treated cells and their control, and for uPA and MET 
expression. Receiver-operating curves (ROC) were 
conducted to determine ability of miR-23b and miR-
193a to discriminate between tumor and PT tissues. For 
survival curves, Kaplan-Meier analyses were conducted 
using 30 cases. Analysis of variance (ANOVA) followed 
by post-hoc Tukey test was applied to discern significant 
differences in the proliferation assays. Correlation 
between miR-23b/193a expression levels and clinical 
and pathological characteristics was evaluated using Chi-
square test. Data were considered significant when P-value 
≤ 0.05.
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